Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The L-type calcium channel CaV1.2 (vascular smooth muscle isoform) is a voltage-gated ion channel that serves as the primary pathway for Ca2+ influx in vascular smooth muscle cells (VSMCs), enabling membrane depolarization-induced contraction and maintenance of myogenic tone. Composed of a pore-forming α1C (CaV1.2) subunit along with auxiliary β (predominantly β3), α2δ, and γ subunits, it forms heteromeric complexes that regulate channel trafficking, gating, and Ca2+ selectivity. Activation occurs at depolarized potentials typical of VSMCs, coupling pressure or agonist-induced depolarization to Ca2+ entry that triggers contraction via calmodulin and RhoA pathways. It is essential for autoregulation of blood flow, phenylephrine- or angiotensin II-induced vasoconstriction, and blood pressure control, as evidenced by smooth muscle-specific knockout studies showing abolished L-type currents, blunted vasoconstriction, and reduced myogenic responses. In disease, dysregulation contributes to hypertension and vascular hypercontractility; its expression correlates with VSMC differentiation markers like SM α-actin and myosin heavy chain. Therapeutically, it is targeted by calcium channel blockers (e.g., dihydropyridines) that inhibit Ca2+ entry to promote vasodilation, though challenges include isoform-specific regulation and off-target effects on cardiac channels.
Calcium channel blockade inhibiting Ca2+ influx to reduce vascular smooth muscle contraction and blood pressure, Voltage-dependent inhibition of Ca2+ current
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on L-type calcium channel CaV1.2 (vascular smooth muscle isoform) (CaV1.2).